Advanced search
Publication Cover
Future Science OA Volume 6, 2020 - Issue 8
Submit an article Journal homepage
4,613
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Estimation of US Patients with Cancer who may Respond to Cytotoxic Chemotherapy

Edward B Maldonado1 Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7018-8462
ORCID Icon,
Scott Parsons1 Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USAORCID Iconhttps://orcid.org/0000-0002-2312-2356
ORCID Icon,
Emerson Y Chen1 Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USAORCID Iconhttps://orcid.org/0000-0003-3035-4478
ORCID Icon,
Alyson Haslam1 Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USAORCID Iconhttps://orcid.org/0000-0002-7876-3978
ORCID Icon &
Vinay Prasad2 Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, 94143, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6110-8221
ORCID Icon
Article: FSO600 | Received 14 Feb 2020, Accepted 15 May 2020, Published online: 25 Jun 2020

References

  • MarquartJ , ChenEY , PrasadV. Estimation of the percentage of US patients with cancer who respond to genome-driven oncology. JAMA Oncol.4(8), 1093–1098 (2018).
  • HaslamA , GillJ , PrasadV. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw. Open3(3), e200423 (2020).
  • HaslamA , PrasadVet al.Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drug. JAMA Netw. Open. 2(5), e192535 (2019).
  • National Comprehensive Cancer Network Guidelines for Treatment of Cancer by Site. National Comprehensive Cancer Network (2018). www.nccn.org/professionals/physician_gls/default.aspx#site
  • SiegelRL , MillerKD , JemalA. Cancer Statistics, 2018. CA Cancer J. Clin.68(1), 7–30 (2018).
  • SunJ , WeiQ , ZhouY , WangJ , LiuQ , XuH. A systematic analysis of FDA-approved anticancer drugs. BMC Syst. Biol.11(Suppl. 5), 87 (2017).
  • PuzanovI , DiabA , AbdallahKet al.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer5(1), 95 (2017).
  • HsuJC , LinJY , HsuMY , LinPC. Effectiveness and safety of immune checkpoint inhibitors: a retrospective study in Taiwan. PLoS ONE13(8), e0202725 (2018).
  • WangDY , SalemJE , CohenJVet al.Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol.4(12), 1721–1728 (2018).
  • MoslehiJJ , DeiningerM. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J. Clin. Oncol.33(35), 4210–4218 (2015).
  • HazimA , MillsG , PrasadV , HaslamA , ChenEY. Relationship between response and dose in published, contemporary Phase I oncology trials. J. Natl Compr. Canc. Netw.18(4), 428–433 (2020).
  • BaillyC , ThuruX , QuesnelB. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer2(1), (2020).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.